VALENCIA, Calif., April 4, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference on April 11, 2007 at 10:20 AM (EDT) at the Millennium Broadway Hotel in New York, NY.

Interested parties can access a link to the live web cast of the presentation in the Investor Relations section of the Company's website at www.mannkindcorp.com. A replay of the presentation will be available for 14 days.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Its lead product, the Technosphere(R) Insulin System, is currently in phase 3 clinical trials in the United States, Europe and Latin America to study its safety and efficacy in the treatment of diabetes. For more information on MannKind Corporation and its technology, visit www.mannkindcorp.com.

SOURCE: MannKind Corporation

Dick Anderson,
Chief Financial Officer of MannKind Corporation,
+1-661-775-5302,
danderson@mannkindcorp.com;
or
Investors, Evan Smith of Financial Dynamics,
+1-212-850-5606,
mnkd@fd.com,
for MannKind Corporation